Mark is an Entrepreneur-in-Residence on the Frazier Life Sciences team and an experienced executive in global biotech and pharma.
Mark joined Frazier Healthcare Partners in 2017 as an Executive-in-Residence and is currently the Chief Executive Officer and Director of Lassen Therapeutics.
Mark brings more than 20 years of leadership and biopharma industry expertise to building companies with Frazier. Prior to joining Frazier, Mark held executive leadership roles in global biotech and pharma. He most recently served as Global Head of Strategy & Business Development at Sanofi Genzyme and was a member of the company’s executive leadership team responsible for managing Sanofi Genzyme’s global businesses in rare diseases, gene therapy, immunology, multiple sclerosis, and oncology.
Mark has been responsible for business development deals and acquisitions with an aggregate value of over $5 billion, including $100+ million in venture financings, and the creation of seven new companies including $130+ million in venture financings. His business development activities have resulted in successful global co-development programs including 200,000+ patients, collaborative worldwide commercialization of blockbuster products, and enabling innovative early stage research to late stage product development and commercialization.
Prior to Genzyme, Mark was a member of Johnson & Johnson’s global business development group responsible for a range of strategic partnering and new venture activities, including the spin-out of IONSYS into Incline Therapeutics in 2010 which was financed by Frazier. Mark was responsible for Janssen’s relationship with venture capital and also helped to launch the Johnson & Johnson Innovation Center in Boston, where he was a founding member.
Mark holds a B.S. in Biology from Duke University and an M.B.A. from the University of California, Berkeley.
University of California, Berkeley (M.B.A.)
Duke University (B.S.)